Kenneth Zangwill, M.D.

Kenneth Zangwill, M.D.
Professor of Clinical Pediatrics
Director, UCLA Center for Vaccine Research
Co-Director, Harbor-UCLA Infection Control Program

Phone: (310) 972-3623
Fax: (310) 972-2962
Email: kzangwill@labiomed.org

Certifications:

Pediatrics
Pediatric Infectious Diseases
Certificate of Knowledge in Clinical Tropical Medicine and Travelers’ Health from the American Society of Tropical Medicine and Hygiene

Experience and Professional Training:

1980-1984 BA, University of Pennsylvania, Philadelphia, Pennsylvania
1984-1988 MD, The Milton S. Hershey Medical Center, Pennsylvania State University,
Hershey, Pennsylvania
1988-1991 Pediatric Residency, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
1991-1993 Epidemic Intelligence Service Officer, Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
1993-1995 Fellow, Pediatric Infectious Diseases, Harbor-UCLA Medical Center

Research Interests:

Dr. Zangwill's research focuses primarily on vaccine-preventable diseases, including natural disease epidemiology and the safety, immunogenicity, and effectiveness of current and experimental vaccines. Most recently these have included influenza (seasonal and pandemic), rotavirus, hepatitis A, meningococcal conjugate, and DTaP-IPV-HepB vaccines.

Selected Publications:

1. Zangwill KM, Vadheim CM, Vannier AM, Hemenway L, Greenberg DP, Ward JI. Epidemiology of pneumococcal disease in Southern California: Implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996;174:752-9.

2. Zangwill KM, Schuchat A, Riedo FX, Pinner RW, Koo DT, Reeves MW, Wenger JD. School-based clusters of meningococcal disease in the United States: Descriptive epidemiology and a case-control analysis. JAMA 1997;277:389-395.

3. Belshe RB, Mendelman P, Treanor J, King J, Gruber WC, Piedra P, Bernstein D, Hayden FG, Kotloff K, Zangwill KM, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. New Engl J Med 1998;338:1408-12.

4. Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001;108:e24 (1-8).

5. Zangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, Chiu C-Y, Jing J, Chang S-J, Cho I, Ward JI. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001;20:740-6.

6. Zangwill KM, Greenberg DP, Chiu C-Y, Mendelman P, Wong VK, Chang S-J, Partridge S, Ward JI. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. Vaccine 2003;21:1894-1900.

7. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: A summary for the new era of routine vaccination. Pediatr Infect Dis J 2004;23:189-200.

8. Eriksen EM, Perlman J, Miller A, Marcy SM, Lee H, Vadheim CD, Zangwill KM, Chen RT, DeStefano F, Lewis E, Black S, Shinefield H. Ward JI. Lack of association between hepatitis b vaccination and neonatal death: A population-based study from the Vaccine Safety Datalink project. Pediatr Infect Dis J 2004;23:656-61.

9. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Evaluation of an inactivated subunit H5N1 influenzavirus vaccine in humans. New Engl J Med 2006;354:1343-51.

10. Jackson LA, Neuzil KM, Baggs, J, Bounds L, Black S, Hambridge S, Belongia E, Zangwill KM, Mullooly J, Nordin J, Marcy SM, Davis RL, DeStefano F. Compliance with the recommendations for two doses of trivalent inactivated influenza vaccine in children less than nine years of age receiving influenza vaccine for the first time: A Vaccine Safety Datalink study. Pediatrics 2006;118:2032-7.

11. Hambridge SJ, Glanz JM, McClure D, France EK, Xu S, Yamasaki K, Jackson LA, Mullooly J, Zangwill KM, et al. Safety of the trivalent influenza vaccine in infants and young children age 6-23 months: A population-based study. JAMA 2006;296:1990-97.

12. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a (third) booster dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197:580-3.

13. Xu, F, Gee JM, Naleway A, Zangwill KM, et al. Incidence of laboratory-confirmed neonatal herpes simplex virus infections in two managed care organizations: implications for surveillance. Sexually Transmitted Diseases 2008; 2008 Jun;35(6):592-8.

14. Batra JS, Eriksen EM, Zangwill KM, et al. Population-based evaluation of vaccine coverage for preterm and low birth weight infants during the first year of life. Pediatrics, in press.

15. Zangwill KM, Eriksen, E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, Ward JI. A population-based, post-licensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B,
inactivated poliovirus combination vaccine in a large managed care organization. Pediatrics, in press.